Stockreport

ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer

ImmunoGen, Inc.  (IMGN) 
Last immunogen, inc. earnings: 5/1 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.immunogen.com/investor-relations
PDF Trial Did Not Meet Primary Endpoint of Progression-Free Survival Efficacy Signal Seen in High Folate Receptor Alpha Patients; Additional Analyses [Read more]